Special review articleThe potential utility of a staging model as a course specifier: A bipolar disorder perspective☆
Section snippets
Michael Berk MBBCh MMed(Psych) FF(Psych)SA FRANZCP PhD. Professor of Psychiatry in the Department of Clinical and Biomedical sciences at The University of Melbourne.
References (14)
- et al.
The evolving bipolar spectrum. Prototypes I, II, III, and IV
Psychiatr. Clin. North Am.
(1999) - et al.
Reduced amygdalar gray matter volume in familial pediatric bipolar disorder
J. Am. Acad. Child. Adolesc. Psychiatry
(2005) - et al.
Clinical definitions of sensitisation in affective disorder: a case register study of prevalence and prediction
J. Affect. Disord.
(1998) - et al.
Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort
Arch. Gen. Psychiatry
(2002) - et al.
Early onset of lithium prophylaxis as a predictor of good long-term outcome
Eur. Arch. Psychiatry. Clin. Neurosci.
(1999) - et al.
“Cade's disease” and beyond: misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder
Can. J. Psychiatry
(2002) - et al.
Do cognitive complaints in euthymic bipolar patients reflect objective cognitive impairment? Psychother
Psychosom.
(2005)
Cited by (135)
App-enhanced transdiagnostic CBT for adolescents with mood or psychotic spectrum disorders
2022, Journal of Affective DisordersBipolar disorder treatment according to illness trajectory: a systematic review of clinical trials
2022, Psychiatry ResearchIllness stage and predominant polarity in bipolar disorder: Correlation with burden of illness and moderation of treatment outcome
2021, Journal of Psychiatric ResearchSpanish validation of the Empirically Developed Clinical Staging Model (EmDe-5) for patients with bipolar disorder
2021, Revista de Psiquiatria y Salud MentalCytokine changes in different types of depression: Specific or general?
2020, Neurology Psychiatry and Brain ResearchOlder Age Bipolar Disorder
2020, Clinics in Geriatric Medicine
Michael Berk MBBCh MMed(Psych) FF(Psych)SA FRANZCP PhD. Professor of Psychiatry in the Department of Clinical and Biomedical sciences at The University of Melbourne.
Karen Hallam BBSc(Hons) PhD. Research Fellow in the Department of Psychiatry at the University of Melbourne.
Patrick McGorry MBBS MD PhD FRCP FRANZCP. Professor of Psychiatry, Clinical and Research Director at O RYGEN Research Centre.
- ☆
Declaration of interest: Professors Berk and McGorry have received research funding and/or program support from pharmaceutical companies that manufacture medications for the treatment of Bipolar Disorder. These include recent research grants from AstraZeneca, and Lilly.